However, magnitude of symptom improvement was greater with the low FODMAP diet<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, June 10, 2025 (HealthDay News) — Adherence to a Mediterranean diet (MD) provides symptom relief in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) or mixed bowel pattern IBS (IBS-M) according to a study published online April 24 in Neurogastroenterology & Motility<\/em>.<\/p>\n Prashant Singh, M.B.B.S., from Michigan Medicine in Ann Arbor, and colleagues conducted a pilot randomized trial to compare the efficacy of the MD to a diet low in fermentable oligo-, di-, monosaccharides, and polyols (low-FODMAP diet [LFD]). Analysis included 20 adults with IBS-D or IBS-M (10 in the MD group and 10 in the LFD group).<\/p>\n The researchers found that 73 percent of the MD group met the primary end point of \u226530 percent decrease in abdominal pain intensity for \u22652\/4\u2009weeks versus 81.8 percent of the LFD group. While not statistically significant, a higher proportion of the LFD group reported adequate relief and met the responder end point for IBS-symptom severity score (SSS; 50-point reduction) versus the MD group (54.6 versus 27.3 percent for IBS-adequate relief and 81.8 versus 45.5 percent for IBS-SSS). Over the four-week treatment period, the LFD group also had a significantly greater reduction in IBS-SSS than the MD group (\u2212105.5 versus \u221260).<\/p>\n “In addition to the issue of being costly and time-consuming, there are concerns about nutrient deficiencies and disordered eating when trying a low FODMAP diet,” Singh said in a statement. “The Mediterranean diet interested us as an alternative that is not an elimination diet and overcomes several of these limitations related to a low FODMAP diet.”<\/p>\n